Pulmonary Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
All the vital news, analysis, and commentary curated by our industry experts.
Pulmonary Tuberculosis Clinical Trials Market Report Overview
The Pulmonary Tuberculosis clinical trial market research report provides an overview of the Pulmonary Tuberculosis Clinical trials scenario. This report provides top-line data relating to the clinical trials on Pulmonary Tuberculosis and an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It also provides prominent drugs for in-progress trials (based on the number of ongoing trials).
|Key Regions||· North America
· Middle East & Africa
· South & Central America
|Key Countries||· South Africa
· United States
|Key Sponsor Types||· Institution
|Leading Sponsors||· Johnson & Johnson
· Otsuka Holdings Co Ltd
· GSK plc
|Enquire & Decide||Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.|
Pulmonary Tuberculosis Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Pulmonary Tuberculosis clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others. Asia-Pacific dominates the market with more than 40% of the clinical trials conducted sas of July 2023.
In the country-wise analysis, South Africa has the highest number of pulmonary tuberculosis clinical trials, as of July 2023. Tanzania has the highest average patient enrollment of pulmonary tuberculosis clinical trials, as of July 2023.
G7 and E7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the UK has the highest proportion of Pulmonary Tuberculosis to Infectious disease clinical trials as of July 2023. While, in the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Pulmonary Tuberculosis to Infectious disease clinical trials as of July 2023.
Pulmonary Tuberculosis Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Pulmonary Tuberculosis clinical trials market, download a free report sample
Pulmonary Tuberculosis Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Pulmonary Tuberculosis clinical trials market are institution, company, and the government. Out of them, the institution sponsor type dominates the market.
Pulmonary Tuberculosis Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Pulmonary Tuberculosis clinical trials market, download a free report sample
Pulmonary Tuberculosis Clinical Trials Market - Competitive Landscape
The leading sponsors in the Pulmonary Tuberculosis clinical trials market are Johnson & Johnson, Otsuka Holdings Co Ltd, Pharmasyntez, GSK plc, and Sanofi among others. Johnson & Johnson led the Pulmonary Tuberculosis clinical trials market in July 2023.
Pulmonary Tuberculosis Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading sponsors in the Pulmonary Tuberculosis clinical trials market, download a free report sample
Segments Covered in the Report
Pulmonary Tuberculosis Clinical Trials Regional Outlook (2023)
- North America
- Middle East & Africa
- South & Central America
Pulmonary Tuberculosis Clinical Trials Country Outlook (2023)
- South Africa
- United States
Pulmonary Tuberculosis Clinical Trials Sponsor Type Outlook (2023)
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies concerning investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Otsuka Holdings Co Ltd
IQVIA Holdings Inc
Cadila Pharmaceuticals Ltd
LegoChem Biosciences Inc
Chengdu Keen Biotechnology Co Ltd
Table of Contents
- 1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2. Report Guidance
- 3. GlobalData Clinical Trials Report Coverage
- 4. Clinical Trials by Region
- 4.1. Clinical Trials and Average Enrollment by Country
- 4.1.1. Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- 4.1.2. Top Five Countries Contributing to Clinical Trials in Europe
- 4.1.3. Top Countries Contributing to Clinical Trials in North America
- 4.1.4. Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- 4.1.5. Top Five Countries Contributing to Clinical Trials in Central and South America
- 4.1. Clinical Trials and Average Enrollment by Country
- 5. Clinical Trials by G7 Countries: Proportion of Pulmonary Tuberculosis to Infectious disease Clinical Trials
- 6. Clinical Trials by Phase in G7 Countries
- 7. Clinical Trials in G7 Countries by Trial Status
- 8. Clinical Trials by E7 Countries: Proportion of Pulmonary Tuberculosis to Infectious disease Clinical Trials
- 9. Clinical Trials by Phase in E7 Countries
- 10. Clinical Trials in E7 Countries by Trial Status
- 11. Clinical Trials by Phase
- 11.1. In Progress Trials by Phase
- 12. Clinical Trials by Trial Status
- 13. Clinical Trials by End Point Status
- 14. Subjects Recruited Over a Period of Time
- 15. Clinical Trials by Sponsor Type
- 16. Prominent Sponsors
- 16.1. Top Companies Participating in Pulmonary Tuberculosis Therapeutics Clinical Trials
- 17. Prominent Drugs
- 18. Clinical Trial Profile Snapshots
- 19. Appendix
- 19.1. Abbreviations
- 19.2. Definitions
- 19.3. Research Methodology
- 19.4. Secondary Research
- 19.5. About GlobalData
- 19.6. Contact Us
- 20. Source
Frequently asked questions
Which was the leading region in the Pulmonary Tuberculosis clinical trials market?
Asia Pacific was the leading region in the Pulmonary Tuberculosis clinical trials market as of July 2023.
Which was the leading country in the Pulmonary Tuberculosis clinical trials market?
South Africa was the leading country in the Pulmonary Tuberculosis clinical trials market as of July 2023.
Which was the leading sponsor type in the Pulmonary Tuberculosis clinical trials market?
Institution was the leading sponsor type in the Pulmonary Tuberculosis clinical trials market as of July 2023.
Who are the leading sponsors in the Pulmonary Tuberculosis clinical trials market?
The leading sponsors in the Pulmonary Tuberculosis clinical trials market are Johnson & Johnson, Otsuka Holdings Co Ltd, Pharmasyntez, GSK plc, and Sanofi among others.
Undecided about purchasing this report?Enquire Before Buying
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.